Clinical Phenotypes of Cystic Fibrosis Carriers.
Where this comes from
- Record sourced from PubMed, PMID 35084992.
- Also identified by DOI 10.1146/annurev-med-042120-020148 and PMC identifier 8884701.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cystic fibrosis (CF) is an autosomal recessive genetic disorder caused by mutations in <i>CFTR</i>, the cystic fibrosis transmembrane conductance regulator gene. People with CF experience a wide variety of medical conditions that affect the pulmonary, endocrine, gastrointestinal, pancreatic, biliary, and reproductive systems. Traditionally, CF carriers, with one defective copy of <i>CFTR</i>, were not thought to be at risk for CF-associated diseases. However, an emerging body of literature suggests that heterozygotes are at increased risk for many of the same conditions as homozygotes. For example, heterozygotes appear to be at increased risk for chronic pancreatitis, atypical mycobacterial infections, and bronchiectasis. In the United States alone, there are almost 10 million CF carriers. Universal newborn screening and prenatal genetic screening will identify more. Thus, there is a critical need to develop more precise estimates of health risks attributable to the CF carrier state across the lifespan.
Medical subject headings
- Cystic Fibrosis